Comment by
nozzpack on Aug 14, 2020 9:06am
I should add that Cipher will continue to receive a royalty until December 2024 based on U.S. net sales from Sun’s Absorica LD drug. I cannot forecast that level from Nov 2022 to Dec 2024, but most probably above $10 million US per year. In Summary, Absorica revenues in the US will continue to be a cash cow for Cipher
Comment by
pabaloo on Aug 14, 2020 12:27pm
Exactly! The money will continue to roll in no hurry to do anything. 10 million a year for the foreseeable future. With Trulance and Trevyent possibly 15 million in royalties. Lots of possibilities and the downside is minimal. There is also almost 200 million in NOLS that can be used to offset tax gains. The future is bright no need to worry here just enjoy the ride.
Comment by
spike55 on Aug 14, 2020 12:38pm
Thats right in a low return world this stock will outperform.....I give it a 20X earnings (excluding Absorica)
Comment by
nozzpack on Aug 14, 2020 5:14pm
Your futile posting here confirms your idiocy. Really, you know, not all people are as dumb as yourself. Got It ?
Comment by
pabaloo on Aug 16, 2020 9:25pm
I have owned a dozen companies that had the option to buy back shares and only 1 has ever done it to any degree. Let's hope Cipher actually starts to buy back shares right out of the gate until the feel it's shares are fairly priced. You are correct in that this stock will jump if the company starts to accumulate the few thousand shares every week that are sold at market.